Evaluation of the effect of i.v. Bondronat [ibandronic acid] followed by maintenance treatment with oral Bondronat on pain response in patients with bone metastases from breast cancer or multiple myeloma experiencing moderate to severe pain

Trial Profile

Evaluation of the effect of i.v. Bondronat [ibandronic acid] followed by maintenance treatment with oral Bondronat on pain response in patients with bone metastases from breast cancer or multiple myeloma experiencing moderate to severe pain

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2010

At a glance

  • Drugs Ibandronic acid (Primary)
  • Indications Advanced breast cancer; Cancer metastases; Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2010 Planned number of patients changed from 60 to 53 as reported by ROche record.
    • 16 Apr 2008 Status changed from in progress to completed.
    • 09 Jan 2008 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top